Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms

Creative Commons License

DUMAN B., Sedes N., BASKAK B.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.54, sa.1, ss.38-42, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 54 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5152/npa.2017.16964
  • Dergi Adı: NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.38-42
  • Anahtar Kelimeler: Psychotic disorders, substance-related disorders, substance-induced psychosis, SCHIZOTYPAL PERSONALITY, PREPULSE INHIBITION, ECSTASY MDMA, EXPOSURE, ENVIRONMENT, SPQ
  • Ankara Üniversitesi Adresli: Evet

Özet

Introduction: Methylenedioxymethamphetamine (MDMA) is an amphetamine- derived psychostimulant, usually known as "ecstasy." The long-term neuropsychological effects of MDMA are examined in several studies with conflicting results. The most common findings reported are depression, anxiety, and memory and attention deficits. In addition to acute psychotic reactions observed after MDMA use, serotonergic and dopaminergic toxicities may increase the psychosis risk in the long-term. Cannabis usage among MDMA users is very high. The aim of this study was, therefore, to examine the additive effects of cannabis and MDMA on subclinical psychotic symptoms (SPS).